OLODANRIGAN SODIUM

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C32H28NO5.Na
Molecular Weight	529.5582
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].COC1=C(OCC2=CC=CC=C2)C3=C(CN([C@@H](C3)C([O-])=O)C(=O)C(C4=CC=CC=C4)C5=CC=CC=C5)C=C1

InChI

InChIKey=AKMGNOBRQGBYJM-YCBFMBTMSA-M

InChI=1S/C32H29NO5.Na/c1-37-28-18-17-25-20-33(31(34)29(23-13-7-3-8-14-23)24-15-9-4-10-16-24)27(32(35)36)19-26(25)30(28)38-21-22-11-5-2-6-12-22;/h2-18,27,29H,19-21H2,1H3,(H,35,36);/q;+1/p-1/t27-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C32H28NO5
Molecular Weight	506.5684
Charge	-1
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://adisinsight.springer.com/drugs/800022957 | https://www.ncbi.nlm.nih.gov/pubmed/28255254 | https://www.ncbi.nlm.nih.gov/pubmed/26111701

Olodanrigan (EMA-401) is an angiotensin II type 2 receptor antagonist. Olodanrigan may act on paracrine/autocrine mechanisms at peripheral nerve terminals, or intracrine mechanisms, to reduce neuropathic pain signalling in AngII/NGF/TRPV1-convergent pathways. Olodanrigan is being developed by Novartis for the treatment of neuropathic pain.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Angiotensin II type 2 (AT-2) receptor 10 Target ID: CHEMBL4607 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23489258 \| https://www.ncbi.nlm.nih.gov/pubmed/8576904	Antagonist 2849		0.6 nM [IC50]

PubMed

Title	Date	PubMed
EMA401: an old antagonist of the AT2R for a new indication in neuropathic pain.	2017	28255254
Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies.	2015-06-26	26111701
Development of EMA401 as an orally-administered, highly-selective angiotensin II type 2 receptor antagonist for the treatment of neuropathic pain.	2014-10	25269730
EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial.	2014-05-10	24507377

Sample Use Guides

In Vivo Use Guide

A pilot phase IIa study demonstrated the efficacy and safety of the drug taken twice daily as two capsules of 50 mg (400 mg/day).

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:49:26 GMT 2025` Edited by `admin` on `Mon Mar 31 21:49:26 GMT 2025`
Record UNII	P9EW7EP34P
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

EMA-401 SODIUM

Preferred Name

English

OLODANRIGAN SODIUM

Common Name

English

PD-126055 SODIUM

Code

English

3-ISOQUINOLINECARBOXYLIC ACID, 2-(2,2-DIPHENYLACETYL)-1,2,3,4-TETRAHYDRO-6-METHOXY-5-(PHENYLMETHOXY)-, SODIUM SALT (1:1), (3S)-

Systematic Name

English

EMA401 SODIUM

Code

English

Code System Code Type Description

CAS

1316755-17-5